ISG stabilizes Q3 sales in wake of proxy fight

Article

ISG stabilizes Q3 salein wake of proxy fightMedical imaging software developer ISG Technologies of Mississauga, Ontario, reported a recovery in sales revenue in its third quarter of fiscal 1997 (end-March), the first full quarter following the

ISG stabilizes Q3 salein wake of proxy fight

Medical imaging software developer ISG Technologies of Mississauga, Ontario, reported a recovery in sales revenue in its third quarter of fiscal 1997 (end-March), the first full quarter following the end of a proxy battle for control of the company.

For the third quarter, ISG reported revenues of $5.7 million ($7.8 million Canadian). The amount was equal to ISG's sales in the third quarter of 1996, but represented a 24% increase compared with the second quarter of 1997, when ISG sales plummeted, due to customer anxiety about the proxy fight. ISG in December defeated the proxy bid, which was launched by a dissident shareholder group (PNN 5/97).

ISG posted a loss for the most recent quarter of $256,000, an amount that included proxy costs of $106,000. In the third quarter of fiscal 1996, ISG posted net income of $74,000.

In a conference call with analysts, ISG chairman and CEO Dr. Michael Greenberg said the company saw its strongest growth in its PACS software line of products, which include the Viewing and Reading Stations (VRS) line of image-review workstations. VRS sales doubled in the quarter, Greenberg said.

ISG inked a licensing deal with Imnet in March, in which Imnet agreed to pay $7.8 million (U.S.) for rights to include VRS in its information systems products. ISG plans to recognize that revenue conservatively by spreading it out in several stages over the next few quarters.

Newsletter

Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.

Recent Videos
SNMMI: Emerging PET Insights on Neuroinflammation with Progressive Apraxia of Speech (PAOS) and Parkinson-Plus Syndrome
Improving Access to Nuclear Imaging: An Interview with SNMMI President Jean-Luc C. Urbain, MD, PhD
SNMMI: 18F-Piflufolastat PSMA PET/CT Offers High PPV for Local PCa Recurrence Regardless of PSA Level
SNMMI: NIH Researcher Discusses Potential of 18F-Fluciclovine for Multiple Myeloma Detection
SNMMI: What Tau PET Findings May Reveal About Modifiable Factors for Alzheimer’s Disease
Emerging Insights on the Use of FES PET for Women with Lobular Breast Cancer
Can Generative AI Reinvent Radiology Reporting?: An Interview with Samir Abboud, MD
Mammography Study Reveals Over Sixfold Higher Risk of Advanced Cancer Presentation with Symptom-Detected Cancers
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
Related Content
© 2025 MJH Life Sciences

All rights reserved.